Solid Biosciences (SLDB) Stock Statistics & Valuation Metrics

Solid Biosciences has a market cap or net worth of $793.50M. The enterprise value is $429.99.

Solid Biosciences has 98,449,610 shares outstanding. The number of shares has decreased by -2.65% in one year.

Solid Biosciences’s return on equity (ROE) is -0.97 and return on invested capital (ROIC) is -89.08%.

The current PE Ratio of Solid Biosciences is ―. Solid Biosciences’s PEG ratio is 0.08.

In the last 12 months, Solid Biosciences had revenue of 0.00 and earned -174.32M in profits. Earnings per share was -1.99.

In the last 12 months, operating cash flow was -234.07M and capital expenditures -1.13M, giving a free cash flow of -235.20M billion.

Solid Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―

Solid Biosciences upcoming earnings date is Nov 11, 2026, TBA (Confirmed).

Solid Biosciences as a current ratio of 6.14, with Debt / Equity ratio of 5.39%

In the past 12 months, Solid Biosciences has paid 0.00 in taxes.

Solid Biosciences EV to EBITDA ratio is -2.63, with an EV/FCF ratio of -2.89.

Solid Biosciences has $377.68M in cash and marketable securities with $20.16M in debt, giving a net cash position of $357.52M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Solid Biosciences is $16.75, which is 11.43% higher than the current price. The consensus rating is Strong Buy